This paper describes the optimization efforts to establish an enabling synthesis to provide multigram quantity of PF-00868554, an HCV polymerase inhibitor currently in phase II clinical evaluations.
本文介绍了为提供多克级 PF-00868554 而进行的优化工作,PF-00868554 是一种 HCV 聚合酶
抑制剂,目前正处于二期临床评估阶段。